Biocryst Influeza treatment drug RAPIVAB an intravenous drug to treat acute, uncomplicated influenza has been approved by Health Canada.
Seqirus is commercializing RAPIVAB globally and is a leader in influenza prevention through the supply of vaccine to global markets.
RAPIVAB is an intravenous drug to treat acute uncomplicated influenza in patients 18 years old and above who have been symptomatic no more than two days.
The most common adverse reaction to the drug is diarrhea. There is also risk of neuropsychiatric events such as delirium and confusion and serious skin reactions.
Jon Stonehouse, BioCryst CEO states that they are excited that the drug is now available to patients in Canada and the I.V. drug will be an option to Canadians who are afflicted with influenza.
With the approval of the BioCryst influenza treatment drug will be available in five countries according to a report by ForexTV.
There are two main types of influenza virus. Type A and B viruses routinely spread in people and cause seasonal influenza epidemics each year.
Treatment for flu usually only involves bed rest and drinking of plenty of fluids to treat the flu. But in some cases, the doctor may prescribe antiviral medication. If taken soon after noticing flu symptoms, these medications may shorten the illness by a day and prevent complications.
Aside from anti-viral medications to treat flu, there are a number of medications to treat the symptoms of the illness.
For nasal congestion, decongestants are used to relieve the stuffiness. Decongestants are available in oral or nasal sprays.
Antihistamine is used for post nasal drip and watery and itchy eyes. Antihistamine relieves itching and sneezing and nasal discharge.
For fever there are a number of medications that can bring down the temperature of a person who is down with the flu. Always check with your doctor and or pharmacist to know what kind of antipyretic is safe for you to use, according to an WebMD Magazine.
